No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Chengdu Kanghong Pharmaceuticals Group Co., Ltd operates within China, focusing on the research, development, production, and marketing of a wide array of pharmaceutical goods. These include biologics, traditional Chinese medicines, and chemical drugs. The company's offerings span treatments for ophthalmic ailments, central nervous system conditions, digestive disorders, and other therapeutic areas. Founded in 1996, its corporate headquarters are located in Chengdu, China.
www.cnkh.comNo one on the platform currently holds 002773.SZ.
No tracked institution reports a position in 002773.SZ as of their last filing.
No one on the platform has traded 002773.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 38.3% | 30.2% | — | — | — | |
| Rev. Growth % | 3.0% | 6.8% | ||||
| Profit Margin % | 25.4% | 23.3% | 19.7% | |||
| Free Cash Flow Margin % | 27.1% | 19.4% | 12.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.6B | -5.4% | $1.08 | $1.08–$1.08 | — | 1 |
| 2027 | $5.1B | +10.2% | $1.26 | $1.26–$1.26 | — | 1 |
| 2028 | $5.3B | +4.1% | $1.43 | $1.43–$1.43 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-25 | $0.03 | $0.28 | +833.3% |
| 2026-04-22 | $0.19 | $0.33 | +73.7% |
| 2026-04-22 | $0.20 | $0.14 | -30.0% |
| 2025-10-28 | $0.21 | $0.33 | +57.1% |
| 2025-08-27 | $0.19 | $0.36 | +89.5% |
| 2025-04-25 | $0.03 | $0.43 | +1333.3% |
| 2025-04-25 | $0.03 | $0.24 | +700.0% |
| 2024-10-24 | $0.03 | $0.31 | +933.3% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd | $19.13 | -0.16% | $17.6B | — |
| 000423.SZDong-E-E-Jiao Co.,Ltd. | $46.11 | -0.77% | $29.5B | — |
| 000513.SZLivzon Pharmaceutical Group Inc. | $26.58 | -1.56% | $23.6B | — |
| 000623.SZJilin Aodong Pharmaceutical Group Co., Ltd. | $17.40 | -1.02% | $20.8B | — |
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. |
| $21.65 |
| -0.64% |
| $22.0B |
| — |
| 600079.SSHumanwell Healthcare (Group) Co.,Ltd. | $18.50 | -0.22% | $30.2B | — |
| 600329.SSTianjin Pharmaceutical Da Ren Tang Group Corporation Limited | $34.08 | -1.59% | $19.4B | — |
Source: Financial Modeling Prep · peers by sector/industry